Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas

Journal of Neuro-Oncology

Volumn 83, Issue 2, 2007, Pages 153-162

  Yoshino, Atsuo ^a   Katayama, Yoichi ^a   Ogino, Akiyoshi ^a   Watanabe, Takao ^a   Yachi, Kazunari ^a   Ohta, Takashi ^a   Komine, Chiaki ^a   Yokoyama, Takakazu ^a   Fukushima, Takao ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell cycle regulatory gene; Epigenetic change; Methylation; Pituitary adenoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GENOMIC DNA; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P73; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PROMOTER REGION;

ADENOMA; ADOLESCENT; ADULT; AGED; CELL CYCLE PROTEINS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METHYLATION; MIDDLE AGED; PITUITARY NEOPLASMS; PROMOTER REGIONS (GENETICS); RETINOBLASTOMA PROTEIN;

EID: 34248993306     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9316-9     Document Type: Article

References (66)

1. Alexander JM, Biller BMK, Bikkal H et al (1990) Clinically non-functioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336-401
2. Herman V, Fagin J, Gonsky R et al (1990) Clonal origins of pituitary adenomas. J Clin Endocrinol Metab 71:1427-1433
3. Shimon I, Melmed S (1997) Pituitary tumors pathogenesis. J Clin Endocrinol Metab 82:1675-1681
4. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707
5. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261
6. Sherr CJ (1996) Cancer cell cycles. Science 274:1672-1677
7. Dulic V, Kaufmann WK, Wilson SJ (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023
8. Quelle DE, Zindy F, Ashmun RA et al (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000
9. Kamijo T, Weber JD, Zambetti G et al (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292-8297
10. Pomerantz J, Schreiber-Agus N, Liegeois NJ et al (1998) The INK4a tumor suppressor gene product, p19 Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723
11. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734
12. Esteller M, Corn PC, Baylin SB et al (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229
13. Xu XL, Yu J, Zhang HY et al (2004) Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 23:3441-3454
14. Kawamata N, Inagaki N, Mizumura S et al (2005) Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/ Cip1, p27Kip1 and p73) in natural killer cell disorders. Eur J Haematol 74:424-429
15. INK4A/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64:398-403
16. Brüstle O, Ohgaki H, Schmitt HP et al (1992) Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children: Association with an activated K-ras gene. Cancer 69:2385-2392
17. Herman JG, Graff JR, Myöhänen S et al (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826
18. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159-168
19. INK4a genes in oligodendrogliomas. Acta Neuropathol 101:185-189
20. Watanabe T, Yokoo H, Yokoo M et al (2001) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60:1181-1189
21. Watanabe T, Huang H, Nakamura M et al (2002) Methylation of the p73 gene in gliomas. Acta Neuropathol 104:357-362
22. ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 9:4884-4890
23. Yoshino A, Katayama Y, Fukushima T et al (2003) Telomerase activity in pituitary adenomas: Significance of telomerase expression in predicting pituitary adenoma recurrence. J Neurooncol 63:155-162
24. Karp JE, Broder S (1995) Molecular foundations of cancer: New targets for intervention. Nat Med 1:309-320
25. Ng MHL, Chung YF, Lo KW et al (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89:2500-2506
26. Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436-440
27. Cairns P, Polascik TJ, Eby Y et al (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11:210-212
28. Shapiro GI, Park JE, Edwards CD et al (1995) Multiple mechanisms of p16 INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55:6200-6209
29. Ueki K, Ono Y, Hensen JW et al (1996) CDKN2/p16 or Rb alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153
30. Woloschak M, Yu A, Xiao J et al (1996) Frequent loss of the p16 INK4a gene product in pituitary tumors. Cancer Res 56:2493-2496
31. Farrell WE, Simpson DJ, Bicknell JE et al (1997) Chromosome 9p deletions in invasive and non-invasive non-functional pituitary adenomas: The deleted region involves markers outside of the MTS1 and MTS2 gene. Cancer Res 57:2703-2709
32. INK4B genes in human pituitary adenomas. Eur J Endocrinol 136:74-80
33. Weinberg RA (1992) Tumor supressor genes. Science 254:1138-1146
34. Benedict WF, Xu H, Hu S et al (1990) Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 85:988-993
35. Jacks T, Fazeli A, Schmitt EM et al (1992) Effects of an Rb mutation in the mouse. Nature 359:295-300
36. + mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021-1027
37. Cryns VL, Alexander JM, Klibanski A et al (1993) The retinoblastoma gene in human pituitary tumours. J Clin Endocrinol Metab 77:644-646
38. Woloschak M, Roberts JL, Post KD (1994) Loss of heterozygosity at the retinoblastoma locus in human pituitary tumors. Cancer 74:693-696
39. Zhu J, Leon SP, Beggs AH et al (1994) Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J Clin Endocrinol Metab 78:922-927
40. Pei L, Melmed S, Scheithauer B et al (1995) Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence of a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55:1613-1616
41. Woloschak M, Yu A, Xiao J et al (1996) Abundance and state of phosphorylation of the Rb gene product in human pituitary tumors. Int J Cancer 67:16-19
42. Ohta T, Watanabe T, Katayama Y et al (2006) Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas. Oncol Rep 16:957-963
43. kip1 deficient mice. Cell 85:733-744
44. Kip1. Cell 85:721-732
45. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720
46. Lloyd RV, Erickson LA, Jin L et al (1999) p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 54:313-323
47. Faglia G, Spada A (2001) Genesis of pituitary adenomas: State of the art. J Neurooncol 54:95-110
48. Lloyd RV (2001) Molecular pathology of pituitary adenomas. J Neurooncol 54:111-119
49. Dahia PL, Aguiar RC, Honegger J et al (1998) Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 16:69-76
50. Ikeda H, Yoshimoto T, Shida N (1997) Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer 76:1119-1123
51. Qian X, Jin L, Kulig E et al (1998) DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 153:1475-1482
52. Loda M, Cukor B, Tam SW et al (1997) Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat Med 3:231-234
53. Kaghad M, Bonnet H, Yang A et al (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819
54. Jost CA, Marin MC, Kaelin WG Jr (1997) p73 is a simian (correction of human) p53-related protein that can induce apoptosis. Nature 389:191-194
55. Corn PG, Kuerbitz SJ, van Noesel MM et al (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5'pG island methylation. Cancer Res 59:3352-3356
56. Ichimiya S, Nimura Y, Kageyama H et al (1999) p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18:1061-1066
57. Kawano S, Miller CW, Gombart AF et al (1999) Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94:1113-1120
58. Bello MJ, De Campos JM, Isla A et al (2006) Promoter CpG methylation of multiple genes in pituitary adenomas: Frequent involvement of caspase-8. Oncol Rep 15:443-448
59. Palmero I, Peters G (1996) Perturbation of cell cycle regulations in human cancer. Cancer Surv 27:351-367
60. Burns KL, Ueki K, Jhung SL (1998) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57:122-130
61. Hibberts NA, Simpson DJ, Bicknell JE (1999) Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumours. Clin Cancer Res 5:2133-2139
62. Xing EP, Nie Y, Song Y et al (1999) Mechanisms of inactivation of p14 ARF, p15 INK4b, and p16 INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 5:2704-2713
63. Garcia MJ, Martinez-Delgado B, Cebrian A et al (2002) Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am J Pathol 161:1007-1013
64. Kwong J, Lo KW, To KF et al (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8:131-137
65. Herman JG, Civin CI, Issa JP et al (1997) Distinct patterns of inactivation of p15INK4b and p16INK4a characterize the major types of hematological malignancies. Cancer Res 57:837-841
66. Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2003) Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17:1813-1819